These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 38891834)
1. Cross-Species Insights into Autosomal Dominant Polycystic Kidney Disease: Provide an Alternative View on Research Advancement. Luo J; Zhang Y; Jayaprakash S; Zhuang L; He J Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891834 [TBL] [Abstract][Full Text] [Related]
2. Fibrosis and progression of autosomal dominant polycystic kidney disease (ADPKD). Norman J Biochim Biophys Acta; 2011 Oct; 1812(10):1327-36. PubMed ID: 21745567 [TBL] [Abstract][Full Text] [Related]
4. Recent advances in management of autosomal-dominant polycystic kidney disease. Potts JW; Mousa SA Am J Health Syst Pharm; 2017 Dec; 74(23):1959-1968. PubMed ID: 29167138 [TBL] [Abstract][Full Text] [Related]
5. Inhibiting the HSP90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney disease. Seeger-Nukpezah T; Proia DA; Egleston BL; Nikonova AS; Kent T; Cai KQ; Hensley HH; Ying W; Chimmanamada D; Serebriiskii IG; Golemis EA Proc Natl Acad Sci U S A; 2013 Jul; 110(31):12786-91. PubMed ID: 23858461 [TBL] [Abstract][Full Text] [Related]
6. Soluble receptor for advanced glycation end products inhibits disease progression in autosomal dominant polycystic kidney disease by down-regulating cell proliferation. Lee EJ; Park EY; Mun H; Chang E; Ko JY; Kim DY; Park JH FASEB J; 2015 Aug; 29(8):3506-14. PubMed ID: 25934702 [TBL] [Abstract][Full Text] [Related]
7. Cardamonin retards progression of autosomal dominant polycystic kidney disease via inhibiting renal cyst growth and interstitial fibrosis. He J; Zhou H; Meng J; Zhang S; Li X; Wang S; Shao G; Jin W; Geng X; Zhu S; Yang B Pharmacol Res; 2020 May; 155():104751. PubMed ID: 32151678 [TBL] [Abstract][Full Text] [Related]
8. Genome-Scale Single Nucleotide Resolution Analysis of DNA Methylation in Human Autosomal Dominant Polycystic Kidney Disease. Bowden SA; Rodger EJ; Bates M; Chatterjee A; Eccles MR; Stayner C Am J Nephrol; 2018; 48(6):415-424. PubMed ID: 30463078 [TBL] [Abstract][Full Text] [Related]
9. Autosomal dominant polycystic kidney disease and pioglitazone for its therapy: a comprehensive review with an emphasis on the molecular pathogenesis and pharmacological aspects. Saini AK; Saini R; Singh S Mol Med; 2020 Dec; 26(1):128. PubMed ID: 33308138 [TBL] [Abstract][Full Text] [Related]
10. Monoallelic pathogenic ALG5 variants cause atypical polycystic kidney disease and interstitial fibrosis. Lemoine H; Raud L; Foulquier F; Sayer JA; Lambert B; Olinger E; Lefèvre S; Knebelmann B; Harris PC; Trouvé P; Desprès A; Duneau G; Matignon M; Poyet A; Jourde-Chiche N; Guerrot D; Lemoine S; Seret G; Barroso-Gil M; Bingham C; Gilbert R; ; ; Le Meur Y; Audrézet MP; Cornec-Le Gall E Am J Hum Genet; 2022 Aug; 109(8):1484-1499. PubMed ID: 35896117 [TBL] [Abstract][Full Text] [Related]
11. Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease: A Biomarker of Disease Progression and Therapeutic Efficacy. Alam A; Dahl NK; Lipschutz JH; Rossetti S; Smith P; Sapir D; Weinstein J; McFarlane P; Bichet DG Am J Kidney Dis; 2015 Oct; 66(4):564-76. PubMed ID: 25960302 [TBL] [Abstract][Full Text] [Related]
12. Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model. Pastor-Soler NM; Li H; Pham J; Rivera D; Ho PY; Mancino V; Saitta B; Hallows KR Am J Physiol Renal Physiol; 2022 Jan; 322(1):F27-F41. PubMed ID: 34806449 [TBL] [Abstract][Full Text] [Related]
13. [Research progress in autosomal dominant polycystic kidney disease]. Hu S; Li D; Tan X; Gu J; Chen M; Zhang X Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2019 Oct; 44(10):1179-1187. PubMed ID: 31857514 [TBL] [Abstract][Full Text] [Related]
14. Perspectives of Gene Therapies in Autosomal Dominant Polycystic Kidney Disease. Xu Y; Li A; Wu G; Liang C Curr Gene Ther; 2017; 17(1):43-49. PubMed ID: 28494735 [TBL] [Abstract][Full Text] [Related]
15. An Overview of In Vivo and In Vitro Models for Autosomal Dominant Polycystic Kidney Disease: A Journey from 3D-Cysts to Mini-Pigs. Koslowski S; Latapy C; Auvray P; Blondel M; Meijer L Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630605 [TBL] [Abstract][Full Text] [Related]
16. [Tolvaptan, a vasopressin V Yamada Y; Fujiki H; Mizuguchi H; Takeshita Y; Hattori K; Ohmoto K; Aihara M; Nagano K; Isakari Y; Yamamoto M; Yamamura Y Nihon Yakurigaku Zasshi; 2022; 157(4):254-260. PubMed ID: 35781456 [TBL] [Abstract][Full Text] [Related]
17. The Jeremiah Metzger Lecture. Polycystic kidney disease: old disease in a new context. Grantham JJ Trans Am Clin Climatol Assoc; 2002; 113():211-24; discussion 224-6. PubMed ID: 12053711 [TBL] [Abstract][Full Text] [Related]
18. The spectrum of autosomal dominant polycystic kidney disease in children and adolescents. Reddy BV; Chapman AB Pediatr Nephrol; 2017 Jan; 32(1):31-42. PubMed ID: 27034070 [TBL] [Abstract][Full Text] [Related]